IVIG

Ramucirumab (Cyramza; Eli Lilly) is FDA-approved for 5 unique cancer indications.

The risk of developing acute renal failure and septic shock were higher for individuals with necrotizing soft-tissue infections treated with immunoglobulins, investigators say.

Epcoritamab is an investigational immunoglobulin G1-bispecific antibody being evaluated as a treatment for patients with follicular lymphoma in multiple clinical trials.

Study results show immunoglobulin G antibodies were detected in 13 of 382 individuals in the first phase and 71 of 168 in the second, with age and vaccination status contributing factors.

Immunoglobulin G is among clinical features linked to recurrence of polyps following endoscopic sinus surgery for chronic rhinosinusitis.

Findings of the study, published in International Immunopharmacology, also show that timing and patient selection is an important factor when administering intravenous immunoglobin.

The safety of an anti-coronavirus hyperimmune intravenous immunoglobulin may be influenced by whether an individual is able to naturally generate SARS-CoV-2-neutralizing antibodies.

Investigators also found that intravenous immunoglobulins tend to be associated with increased frequency, though not significant, of serious adverse events.

Efgartigimod alfa-fcab (Vyvgart) is a human immunoglobulin G1 antibody fragment indicated for the treatment of generalized myasthenia gravis.

Tralokinumab-ldrm is a human immunoglobulin G4 monoclonal antibody indicated for the treatment of moderate-to-severe atopic dermatitis.

Anifrolumab-fnia is a human immunoglobulin G (IgG)1κ monoclonal antibody indicated for the treatment of moderate to severe systemic lupus erythematosus.

Immune B cells secrete immunoglobin A antibodies that work on mucosal surfaces in the nose, stomach, and lungs.

Trial seeks to provide high-level evidence for improving the initial treatment for acute Kawasaki disease.

Factor V Leiden can increase the chance of developing abnormal blood clots, most commonly in the legs or lungs.

Families and providers can use a flexible infusion schedule to meet patient needs, Octapharma says.

IVIG also has an important therapeutic role in cases with multisystem inflammatory syndrome in children (MIS-C), the researchers said.

These results are based on a case report of a patient with LCV associated to sensitive neuropathy for whom systemic treatment was ineffective.

IVIG has previously been found to be an effective treatment for heart complications caused by Kawasaki disease.

A study finds that intravenous immunoglobulin therapy is a beneficial way to combat parvovirus-induced PRCA in individuals with anemia.

In its most severe form, Guillain-Barre syndrome is a medical emergency.

Cemiplimab is a recombinant human immunoglobulin G4 monoclonal antibody that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.

Tisotumab vedotin, is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

The existence of immunoglobulin G antibodies specifically indicates recent or prior infection and can help identify individuals with an adaptive immune response to SARS-CoV-2.

An intravenous immunoglobulin option along with glucocorticoids could be effective in fighting drug-induced erythroderma for patients with AIDS.

Study results showed that an individual with the blood disorder did not respond to treatment, including intravenous immunoglobulin, following their second dose of the Pfizer vaccination.

Ado-trastuzumab (Kadcyla, Genentech) was approved by the FDA in 2019 for the adjuvant treatment of patients with human epidermal growth factor receptor 2-positive early breast cancer.

Immune Globulins are injections that are used to treat immunodeficiency disorders.

Patients with chronic inflammatory demyelinating polyneuropathy who transitioned from intravenous immune globulin to subcutaneous immune globulin showed significantly improved quality-of-life measures.

A stepwise approach to treatment for multisystem inflammatory syndrome, beginning with initiation of immunomodulatory drugs, was successful in all patients included in the study.

The FDA has approved the first and only intravenous immunoglobulin indicated for use in adults with dermatomyositis.